Theratechnologies Inc. (TSX:TH)

Market Cap	205.53M
Revenue (ttm)	116.07M
Net Income (ttm)	-12.60M
Shares Out	45.98M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,472
Average Volume	24,063
Open	4.470
Previous Close	4.700
Day's Range	4.360 - 4.530
52-Week Range	1.590 - 4.730
Beta	0.81
RSI	45.96
Earnings Date	Oct 8, 2025

About Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 103
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: TH

Financial Performance

In 2024, Theratechnologies's revenue was $85.87 million, an increase of 5.02% compared to the previous year's $81.76 million. Losses were -$8.31 million, -65.33% less than in 2023.

Financial numbers in USD